<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900900</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00008225</org_study_id>
    <nct_id>NCT00900900</nct_id>
  </id_info>
  <brief_title>The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers</brief_title>
  <acronym>DHEA</acronym>
  <official_title>The Effects of One-Time Pregnenolone, DHEA, Or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jed E. Rose</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the potential therapeutic value of two neurosteroid treatments (DHEA&#xD;
      and pregnenolone) in the treatment of tobacco withdrawal symptoms. This will include&#xD;
      assessing whether these agents relieve craving for cigarettes elicited by exposure to a&#xD;
      mildly stressful cognitive task. Pregnenolone (400 mg orally), DHEA (400 mg orally) and&#xD;
      placebo will be administered one at each of the three sessions in a randomized order.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The administration of DHEA or pregnenolone will reduce smoking withdrawal symptoms.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The administration of DHEA or pregnenolone will reduce the subjective rewarding effects of nicotine inhaled in cigarette smoke.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The administration of DHEA or pregnenolone will reduce stress-induced changes in mood and craving for cigarettes.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Substance Withdrawal Syndrome</condition>
  <arm_group>
    <arm_group_label>Dehydroepiandrosterone (DHEA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregnenolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>dehydroepiandrosterone (DHEA)</intervention_name>
    <description>one-time 400mg oral dose of DHEA</description>
    <arm_group_label>Dehydroepiandrosterone (DHEA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>pregnenolone</intervention_name>
    <description>one-time 400mg oral dose of pregnenolone</description>
    <arm_group_label>Pregnenolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>one-time dose oral dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. male;&#xD;
&#xD;
          2. 18-65 years old;&#xD;
&#xD;
          3. smoked an average of at least 10 cigarettes per day for three cumulative or continuous&#xD;
             years of a brand that delivers (by Federal Trade Commission rated yields) at least 0.5&#xD;
             mg nicotine;&#xD;
&#xD;
          4. afternoon expired carbon monoxide reading of at least 10 ppm;&#xD;
&#xD;
          5. in general good health, based on physical examination, EKG serum chemistries, CBC and&#xD;
             urinalysis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants must not have uncontrolled hypertension (systolic &gt;140 mm Hg, diastolic&#xD;
             &gt;95 mm Hg)&#xD;
&#xD;
          2. hypotension (systolic &lt;90 mm Hg, diastolic &lt;60 mm Hg);&#xD;
&#xD;
          3. coronary heart disease;&#xD;
&#xD;
          4. heart attack;&#xD;
&#xD;
          5. cardiac rhythm disorder (irregular heart rhythm);&#xD;
&#xD;
          6. chest pains (unless history, exam, and EKG clearly indicate a non-cardiac source);&#xD;
&#xD;
          7. cardiac (heart) disorder (including but not limited to valvular heart disease, heart&#xD;
             murmur, heart failure);&#xD;
&#xD;
          8. liver or kidney disorder (except kidney stones, gallstones);&#xD;
&#xD;
          9. gastrointestinal problems or disease other than gastroesophageal reflux,&#xD;
&#xD;
         10. heartburn, or irritable bowel syndrome;&#xD;
&#xD;
         11. ulcers within the past 6 months;&#xD;
&#xD;
         12. lung disorder (including but not limited to COPD, emphysema, and asthma);&#xD;
&#xD;
         13. brain abnormality (including but not limited to, stroke, brain tumor, seizure&#xD;
             disorder);&#xD;
&#xD;
         14. history of fainting;&#xD;
&#xD;
         15. problems giving blood samples;&#xD;
&#xD;
         16. diabetes;&#xD;
&#xD;
         17. current cancer or treatment for cancer in the past 6 months (except basal or squamous&#xD;
             cell skin cancer);&#xD;
&#xD;
         18. other major medical condition;&#xD;
&#xD;
         19. major depression, panic disorder, anxiety, bipolar disorder, schizophrenia, risk of&#xD;
             suicide, or substance dependence other than nicotine dependence;&#xD;
&#xD;
         20. subjects who endorse suicidal ideation on the MINI abridged;&#xD;
&#xD;
         21. alcohol or drugs abuse;&#xD;
&#xD;
         22. reported use of illicit drugs within the past 30 days, or if the drug screen is&#xD;
             positive;&#xD;
&#xD;
         23. reported use of smokeless tobacco (chewing tobacco, snuff), cigars, pipes, or nicotine&#xD;
             replacement therapy; testosterone replacement therapy, DHEA or Pregnenolone;&#xD;
             experimental (investigational) drugs; psychiatric medications (including&#xD;
             antidepressants, anti-anxiety agents. anti-psychotics), sleep aids, medications that&#xD;
             increase DHEA and/or DHEA-S concentrations (including, but not limited to: diltiazem,&#xD;
             benfluorex, amlodipine, alprazolam, danazol, metformin, nitrendipine and retinol), or&#xD;
             any other medications that are known to affect smoking (e.g. clonidine, muscle&#xD;
             relaxants, opiate pain medications) within the past 2 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jed E Rose, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Marx, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Center for Nicotine &amp; Smoking Cessation Research</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Center for Nicotine &amp; Smoking Cessation Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>May 11, 2009</study_first_submitted>
  <study_first_submitted_qc>May 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2009</study_first_posted>
  <disposition_first_submitted>September 10, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>September 14, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 21, 2012</disposition_first_posted>
  <last_update_submitted>September 14, 2012</last_update_submitted>
  <last_update_submitted_qc>September 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Jed E. Rose</investigator_full_name>
    <investigator_title>Professor Department of Psychiatry and Behavorial Sciences</investigator_title>
  </responsible_party>
  <keyword>Cigarette Smokers</keyword>
  <keyword>DHEA</keyword>
  <keyword>dehydroepiandrosterone</keyword>
  <keyword>pregnenolone</keyword>
  <keyword>Nicotine withdrawal symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

